Fast-growing Biopharmaceutical Company NOVADIP Develops its Product Portfolio and Moves to new Premises Offering On-site R&D and GMP Facilities
MONT-SAINT-GUIBERT, Belgium, June 20, 2016 /PRNewswire/ --
NOVADIP BIOSCIENCES, a Biopharmaceutical Spin-off Company of Université catholique de Louvain, Announces the Official Opening of its new Site in Mont-Saint-Guibert, Belgium. The new Facilities Include Work Space for the Growing, 16-person Team, Plus two R&D/QC Labs and State-of-the-art GMP Cleanrooms for Producing Clinical Batches
NOVADIP BIOSCIENCES pioneers the growth of 3-dimensional tissues derived from adipose stem cells to regenerate bone and soft tissues. The flagship of the company's product family is NVD-001, a revolutionary, ready-to-use and biological 3D osteogenic structure that can be modelled to fill large and small bone defects. The technology has also been used to develop the second family product in the portfolio, NVD-002, a biological bandage for skin tissue applications, designed to avoid formation of painful scars.
NOVADIP BIOSCIENCES moved from incubators at St Luc University Hospital and Louvain-la-Neuve to support its rapid growth and achieve its development objectives. The new site, at the Watson & Crick Hill Research and Technology Parc in Mont-St-Guibert, Belgium, is already fitted with state-of-the-art grade A/B cleanrooms, suitable for GMP production of NVD-001 and NVD-002 clinical batches to support NOVADIP's upcoming clinical trials. Starting in December 2015, NOVADIP BIOSCIENCES began refurbishing the site, including setting up two R&D/QC labs for the development and characterisation of new products such as NVD-002, dedicated to wound healing.
"Establishing our new corporate premises is a key step towards fulfilling our mission to propose new therapies in regenerative medicine for a global market," comments Jean-François Pollet, CEO and co-founder. "Direct access to the cleanrooms and R&D/QC labs, as well as space for our rapidly-growing team, will support us to continue moving forward with our products already in development, while also working to realise the broad potential of our technology for multiple applications."
NOVADIP's adipose stem cell technology originates from research lead by Dr. Denis Dufrane (CSO and co-founder) and colleagues at the Cell and Tissue Therapy Centre of St Luc University Hospital and Université catholique de Louvain. To-date, 15 patients with various but severe conditions were cleared for treatment with NVD-001 by Professors Pierre-Louis Docquier and Christian Raftopoulos (St Luc University Hospital) under the European hospital exemption rule, while a further 7 patients have received treatment with NVD-002 by Dr. Aurore Lafosse. Both products showed promising clinical outcomes.
About NOVADIP BIOSCIENCES:
Founded by Dr. Denis Dufrane and Dr. Jean-François Pollet, NOVADIP BIOSCIENCES, a spin-off company from University of Louvain (UCL) and St Luc University Hospital (CUSL), is active in regenerative medicine. NOVADIP is developing a family of products for bone and soft tissue indications, using autologous adipose-derived stem cells, isolated in a minimally-invasive procedure. More information: http://www.NOVADIP.com
About NVD-001 and NVD-002 :
NOVADIP's proprietary NVD-001 is an autologous tissue-engineered product. This scaffold-free, 3-dimensional mouldable and biological 'putty' enables the reconstruction of large and small bone defects without the need of any biomaterial. It is a fully osteogenic, osteoinductive and osteoconductive living implant. The product has already shown signals of safety and substantial enhancement of clinical outcomes in several indications, including congenital and acquired pseudo-arthrosis, and spine fusion.
NVD-002 is a biological bandage for dermal reconstruction, designed to avoid formation of painful scars from wounds resulting from a range of diseases, infections or injuries - such as ulcers, diabetes or third-degree burns - that do not heal as expected. It aims to offer better functional, esthetical and social outcomes for existing and future treatments.
Both NVD-001 and NVD-002 are obtained from adipose-derived mesenchymal stem cells (AMSCs) cells isolated from a minute quantity of the patient's own fatty tissue. The autologous stem cells promote a perfect engraftment and in vivo tissue regeneration with all native bone or skin properties.
SOURCE Novadip Biosciences